Dental Appliance for Sleep Apnea in Children

Not currently recruiting at 3 trial locations

Overseen By Mark Musso, DDS

Age: < 18

Sex: Any

Trial Phase: Phase 4

Sponsor: Vivos BioTechnologies, Inc.

Disqualifiers: Poor oral hygiene, Uncontrolled diabetes, Severe sleep apnea, TMJ, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 1 Jurisdiction This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 1 year

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if a specific mouthguard, the Vivos Grow/Vivos Way Device, can assist children with sleep-disordered breathing, including snoring or mild sleep apnea. The focus is on children planning to undergo orthodontic treatment who have either permanent or mixed teeth. Suitable candidates are children aged 6 to 18 who experience sleep difficulties due to breathing problems but do not have severe sleep apnea or poor oral health. As a Phase 4 trial, this research involves an FDA-approved treatment and seeks to understand its benefits for more patients, offering a chance to improve sleep quality with a proven device.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What is the safety track record for the Vivos Grow/Vivos Way Device?

Research has shown that the Vivos Grow/Vivos Way Device is safe for treating sleep apnea in children. Studies have found that children tolerate this device well, with no major side effects reported. This is crucial for kids who might be sensitive to treatments. Additionally, other studies have used the device for similar conditions and found it both safe and effective. This suggests that the Vivos device could be a promising option for managing sleep apnea symptoms in children. ^{1 2 3 4 5}

Why are researchers enthusiastic about this study treatment?

The Vivos Grow/Vivos Way Device is unique because it offers a non-invasive approach to treating sleep apnea in children, unlike traditional options like CPAP machines or surgery. This dental appliance is designed to naturally expand the jaw and airway, potentially addressing the root cause of sleep apnea instead of just managing symptoms. Researchers are excited about this treatment because it could provide a more comfortable and long-term solution for young patients, reducing the need for lifelong or aggressive interventions.

What evidence suggests that the Vivos Grow/Vivos Way Device is effective for sleep apnea in children?

Research shows that the Vivos Grow/Vivos Way Device, used by participants in this trial, holds promise for treating sleep apnea in children. In earlier studies, 77% of children experienced at least a 50% reduction in their sleep apnea symptoms. Among those with severe sleep apnea, 93% saw a 50% reduction. The device offers a non-surgical, drug-free option approved by the FDA for moderate to severe cases. This approval indicates that the Vivos device can effectively reduce breathing problems during sleep in children. ^{1 2 6 7 8}

Who Is on the Research Team?

Mark Musso, DDS

Principal Investigator

Musso Family Dentistry

Are You a Good Fit for This Trial?

This trial is for children aged 6-18 in the U.S. with sleep-disordered breathing symptoms like snoring or mild to moderate obstructive sleep apnea, who are also getting orthodontic treatment. They must have good oral hygiene and not have severe respiratory conditions, uncontrolled diabetes, braces already on, very large tonsils, or TMJ issues.

Inclusion Criteria

I have been diagnosed with a sleep disorder that affects my breathing.

I am between 6 and 18 years old.

I have decided to undergo orthodontic treatment.

Exclusion Criteria

I have severe sleep apnea with more than 10 interruptions per hour.

My tonsils are very large, taking up most of the space in my throat.

I do not have severe asthma, emphysema, COPD, or similar breathing problems.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants use the Vivos Grow/Vivos Way device to treat sleep-disordered breathing

1 year

Initial evaluation and post-treatment assessment

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Vivos Grow/Vivos Way Device

Trial Overview

The study is testing if a marketed mouthguard (Vivos Grow/Vivos Way Device) can help reduce symptoms of sleep-disordered breathing in children when used alongside their orthodontic treatment.

How Is the Trial Designed?

Group I: Intervention Arm will use Vivos Grow/Vivos Way Device Experimental Treatment 1 Intervention

This intervention will compare measurements prior to treatment with measurements post-treatment.

Vivos Grow/Vivos Way Device is already approved in United States for the following indications:

Approved in United States as Vivos CARE devices for:

• Mild to severe obstructive sleep apnea (OSA)

Who Is Running the Clinical Trial?

Vivos BioTechnologies, Inc.

Lead Sponsor

Trials

1

Recruited

50+

Published Research Related to This Trial

The use of a mandibular advancement intraoral appliance (MOA) in 18 pediatric patients with obstructive sleep apnea syndrome (OSAS) led to a significant reduction in respiratory disturbance index (RDI) from 10 to 4.5 events per hour and an increase in minimum oxygen saturation (SpO2) from 82.6% to 88.9% over 60 days.

The MOA also significantly decreased total snoring events and improved various sleep disorder symptoms without altering signs of temporomandibular disorders, suggesting it can be an effective alternative treatment for OSAS in children.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of a mandibular advancement intraoral appliance (MOA) for the treatment of obstructive sleep apnea syndrome (OSAS) in pediatric patients: A pilot-study. Modesti-Vedolin, G., Chies, C., Chaves-Fagondes, S., et al.[2019]

In a study of 103 children with obstructive sleep apnea syndrome (OSAS), treatment with a custom device that combined maxillary expansion and mandibular advancement led to significant improvements in sleep breathing quality after nine months, as indicated by a decrease in the Apnea/Hypopnea Index to ≤5.

Long-term follow-up revealed that 84% of the patients reported no loud or troubled breathing years after treatment, suggesting lasting benefits from the intervention in improving respiratory status during sleep.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Preliminary results on the impact of simultaneous palatal expansion and mandibular advancement on the respiratory status recorded during sleep in OSAS children. Remy, F., Bonnaure, P., Moisdon, P., et al.[2021]

In a study of 20 patients with mild-to-moderate obstructive sleep apnea, both the individually adjustable intraoral sleep apnea device (ISAD) and CPAP significantly improved apnea/hypopnea index (AHI) and breathing-related arousals, but CPAP was more effective in normalizing respiratory parameters after 6 weeks.

Patients found the ISAD easier to use and reported better compliance compared to CPAP, suggesting that while CPAP is more effective long-term, the ISAD may be a beneficial alternative for those who struggle with CPAP adherence.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An individually adjustable oral appliance vs continuous positive airway pressure in mild-to-moderate obstructive sleep apnea syndrome. Randerath, WJ., Heise, M., Hinz, R., et al.[2019]

A study involving 58 patients with obstructive sleep apnea found that both a new-generation noncustom mandibular advancement device (MAD) and a custom MAD significantly reduced the apnea-hypopnea index, indicating effective treatment for sleep apnea.

The results showed no significant differences in effectiveness between the noncustom and custom MADs, suggesting that noncustom devices could be a viable option for predicting treatment success and improving patient outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Equal effect of a noncustom vs a custom mandibular advancement device in treatment of obstructive sleep apnea. Bosschieter, PFN., Uniken Venema, JAM., Vonk, PE., et al.[2023]

The anterior mandibular positioning (AMP) device significantly reduced the apnoea-hypopnoea index (AHI) and the percentage of time spent snoring, indicating its efficacy in treating obstructive sleep apnoea and snoring.

While patients reported a statistically significant increase in sore teeth, the side effects were generally mild, with no significant increase in facial pain or other discomforts, suggesting the AMP device is a safe treatment option.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Anterior mandibular positioning device for treatment of snoring and obstructive sleep apnoea. Faber, CE., Grymer, L., Hjorth, T.[2004]

In a pilot study of 24 adults with loud snoring, a dental device that advances the mandible and increases vertical dimension (device A) significantly reduced the Respiratory Disturbance Index (RDI) by an average of 14.5 events per hour and improved sleepiness scores after 2 weeks of use.

In contrast, a different device that minimally increased vertical opening without mandible protrusion (device B) did not show any improvement in RDI and even resulted in increased scores for some subjects, highlighting the importance of device design in treating obstructive sleep apnea.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of two dental devices for treatment of obstructive sleep apnea syndrome (OSAS). Hans, MG., Nelson, S., Luks, VG., et al.[2019]

The study involving 96 patients with mild to moderate obstructive sleep apnea found that a custom-made oral appliance significantly reduced the apnea-hypopnea index (AHI) and snoring, with 49% of users achieving an AHI below 5 compared to only 11% in the placebo group.

Despite the reduction in sleep apnea severity and snoring, the oral appliance did not lead to significant improvements in daytime sleepiness or quality of life, indicating that while it may help with sleep apnea symptoms, it does not necessarily enhance overall daytime functioning.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Oral Appliance Therapy in Patients With Daytime Sleepiness and Snoring or Mild to Moderate Sleep Apnea: A Randomized Clinical Trial. Marklund, M., Carlberg, B., Forsgren, L., et al.[2016]

A study involving 80 patients with varying degrees of sleep apnea showed that a built-in thermal sensor in a mandibular advancement device (MAD) provided highly reliable data on device usage, comparable to self-reported diaries.

The analysis of 30 nights of MAD use revealed a very high reliability score (ICC3,1 0.847), indicating that digital tracking can enhance the accuracy of adherence measurements for patients using MADs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Reliability of an adherence monitoring sensor embedded in an oral appliance used for treatment of obstructive sleep apnoea. Gjerde, K., Lehmann, S., Naterstad, IF., et al.[2018]

The mandibular advancement device (MAD) Somnoguard significantly reduced the respiratory disturbance index (RDI) in 44 patients with obstructive sleep apnea (OSA), indicating improved breathing during sleep.

68% of patients experienced either a cure or substantial improvement in their condition, along with a notable increase in minimal oxygen saturation and a decrease in snoring time, demonstrating the device's efficacy as an alternative treatment for those noncompliant with continuous positive airway pressure.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A mandibular advancement device for the ENT office to treat obstructive sleep apnea. Maurer, JT., Huber, K., Verse, T., et al.[2013]

In a pilot study of 20 heavy snorers, the Somnoguard mandibular advancement device (MAD) showed a 65% success rate in reducing the apnea-hypopnea index (AHI) by at least 50%, indicating its efficacy in treating mild obstructive sleep apnea (OSA).

The use of the MAD led to significant reductions in both the snoring index and the Epworth Sleepiness Scale scores at both 1-month and 6-month follow-ups, demonstrating its effectiveness and good tolerance as a non-invasive treatment option.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pilot study of a novel mandibular advancement device for the control of snoring. Vanderveken, OM., Boudewyns, AN., Braem, MJ., et al.[2019]

Citations

1.

vivos.com

vivos.com/clinical-trial-results-in-pediatric-obstructive-sleep-apnea-treatment/

Clinical Trial Results in Pediatric Obstructive Sleep Apnea ...

Groundbreaking Results with the Vivos DNA Appliance · 77% of participants experienced at least a 50% reduction in OSA severity. · Among children ...

2.

vivos.com

vivos.com/new-clinical-trial-data-published-showing-positive-results-from-use-of-vivos-technology-to-treat-obstructive-sleep-apnea-in-children/

New Clinical Trial Data Published Showing Positive ...

A groundbreaking multicenter clinical trial evidencing positive results for the treatment of OSA in children using Vivos' patented Daytime-Nighttime Appliance ...

3.

finance.yahoo.com

finance.yahoo.com/news/vivos-therapeutics-announces-landmark-clinical-123000610.html

Vivos Therapeutics Announces Landmark Clinical Trial ...

77% of participants experienced at least a 50% reduction in OSA severity. Among children with severe OSA, 93% reached a 50% reduction in OSA ...

4.

biospace.com

biospace.com/press-releases/vivos-therapeutics-releases-additional-clinical-data-showing-marked-improvement-in-pediatric-adhd-from-use-of-vivos-dna-device

Vivos Therapeutics Releases Additional Clinical Data ...

In this current dataset just released by Vivos, children treated with the Vivos DNA appliance reported a 50% decrease in the validated Pediatric ...

5.

globenewswire.com

globenewswire.com/news-release/2025/09/30/3158586/0/en/Vivos-Therapeutics-Releases-Additional-Clinical-Data-Showing-Marked-Improvement-in-Pediatric-ADHD-from-Use-of-Vivos-DNA-Device.html

Vivos Therapeutics Releases Additional Clinical Data

Vivos' DNA appliance is the only FDA 510k cleared non-surgical, non-pharmaceutical treatment for moderate to severe pediatric OSA in children ...

6.

vivos.com

vivos.com/vivos-therapeutics-new-data-links-dna-device-to-adhd-relief/

New Data Links DNA Device To ADHD Relief - Vivos

Vivos Therapeutics reveals new clinical data: DNA devices show safe, effective improvement in pediatric ADHD and sleep apnea treatment.

7.

globenewswire.com

globenewswire.com/news-release/2025/09/17/3151624/0/en/Vivos-Therapeutics-Announces-Landmark-Clinical-Trial-Results-in-Pediatric-Obstructive-Sleep-Apnea-Treatment.html

Vivos Therapeutics Announces Landmark Clinical Trial

77% of participants experienced at least a 50% reduction in OSA severity. Among children with severe OSA, 93% reached a 50% reduction in OSA severity.

8.

thevivosinstitute.com

thevivosinstitute.com/a-breakthrough-in-pediatric-osa-treatment-a-removable-oral-appliance-offers-new-hope/

A Breakthrough in Pediatric OSA Treatment: A Removable ...

Importantly, no significant side effects were reported, and the device was well tolerated. The results are particularly meaningful for children ...